53 results
8-K
EX-99.1
APLS
Apellis Pharmaceuticals Inc
27 Feb 24
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
7:30am
(PNH) in the United States, European Union, and other countries globally. The therapy is also under investigation for several other rare diseases
8-K
EX-99.1
APLS
Apellis Pharmaceuticals Inc
8 Jan 24
Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues
9:07am
for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in the United States, European Union, and other countries globally. The therapy is also under
8-K
EX-1.1
wr8 c67g2
1 Nov 23
Entry into a Material Definitive Agreement
7:59am
424B5
8djo1kio
1 Nov 23
Prospectus supplement for primary offering
7:51am
8-K
EX-99.1
nb8bt02s22a2fhf
31 Jul 23
Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results
8:03am
8-K
EX-1.1
hwb2bjz6r2
24 Mar 22
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
8:18pm
424B5
t5i7n3r 15j
24 Mar 22
Prospectus supplement for primary offering
8:02pm
424B5
27yof7
23 Mar 22
Prospectus supplement for primary offering
5:14pm
8-K
EX-1.1
qr641nlh52tbz
20 Jan 22
Entry into a Material Definitive Agreement
4:55pm